 NESS ZIONA, Israel--BUSINESS WIRE--BiomX Inc. NYSE American: PHGE BiomX or the Company, a clinical-stage microbiome company advancing novel natural and engineered phage therapies that target specific pathogenic bacteria, today announced that preclinical results with BX005 in atopic dermatitis were presented at the Revolutionizing Atopic Dermatitis RAD 2021 Virtual Conference and will also be presented at the upcoming International Conference on Phage Therapy and Bacteriophages. RA 